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Abstract
Background: Cryptococcus neoformans infection usually presents as chronic meningitis and is increasingly being
recognized in immunocompromised patients. Presentation with pleural effusion is rare in cryptococcal disease; in
fact, only 4 cases of pleural effusion as the initial clinical presentation in cryptococcosis have been reported in
English-language literature to date. We report the first case of pleural effusion as the initial clinical presentation in a
renal transplant recipient who was initially misdiagnosed with tuberculous pleuritis but who then developed
fungaemia and disseminated cryptococcosis. The examination of this rare manifestation and the accompanying
literature review will contribute to increased recognition of the disease and a reduction in misdiagnoses.
Case presentation: We describe a 63-year-old male renal transplant recipient on an immunosuppressive regimen
who was admitted for left pleural effusion and fever. Cytological examinations and pleural fluid culture were
nonspecific and negative. Thoracoscopy only found chronic, nonspecific inflammation with fibrosis in the pleura.
After empirical anti-tuberculous therapy, the patient developed an elevated temperature, a severe headache and
vomiting and fainted in the ward. Cryptococci were specifically found in the cerebrospinal fluid following lumbar
puncture. Blood cultures were twice positive for C. neoformans one week later. He was transferred to the respiratory
intensive care unit (RICU) immediately and was placed on non-invasive ventilation for respiratory failure for 2 days.
He developed meningoencephalitis and fungaemia with C. neoformans during hospitalization. He was given
amphotericin B liposome combined with 5-flucytosine and voriconazole for first 11 days, then amphotericin B
liposome combined with 5-flucytosine sustained to 8 weeks, after that changed to fluconazole for maintenance. His
condition improved after antifungal treatment, non-invasive ventilation and other support. Further pathological
consultation and periodic acid-Schiff staining revealed Cryptococcus organisms in pleural sections, providing
reliable evidence for cryptococcal pleuritis.
Conclusion: Pleural effusion is an unusual manifestation of cryptococcosis. Cryptococcal infection must be
considered in the case of patients on immunosuppressives, especially solid-organ transplant recipients, who present
with pleural effusion, even if pleural fluid culture is negative. Close communication between the pathologist and
the clinician, multiple special biopsy section stains and careful review are important and may contribute to
decreasing misdiagnosis.
Keywords: Pleural effusion, Meningitis, Organ transplant, Pulmonary fungus, Immunocompromised, Cryptococcosis,
Antifungal therapy
* Correspondence: wzyxywlx@163.com; zjwzhxy@126.com
1Division of Pulmonary Medicine, The First Affiliated Hospital of Wenzhou
Medical University, Key Laboratory of Heart and Lung, Wenzhou, China
Full list of author information is available at the end of the article
© 2015 Chen et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chen et al. BMC Infectious Diseases  (2015) 15:385 
DOI 10.1186/s12879-015-1132-4
Background
Cryptococcosis usually manifests as central nervous sys-
tem (CNS) disease (meningoencephalitis) or pneumonia
[1]. In particular, CNS disease is the most common
Cryptococcus infection among late post-transplant re-
cipients [2]. Pulmonary parenchymal lesions caused by
cryptococcal infection, such as subpleural nodules, inter-
stitial infiltrates, pulmonary masses, alveolar consolidation
and lymphadenopathy, are occasionally encountered as
well [3], whereas pleural effusion in rarely occurs crypto-
coccosis. To our knowledge, only 4 cases of pleural effu-
sion as the initial clinical presentation in cryptococcosis
have been reported in the English-language literature to
date [4–7]. Here, we present the first case of disseminated
cryptococcosis manifesting as meningitis, fungaemia and
cryptococcal pleuritis with an initial clinical presentation
of pleural effusion in a male kidney transplant recipient.
The patient was initially misdiagnosed with tuberculous
pleuritis. The review of the characteristics of this rare case
and discussions related to diagnostic and management is-
sues, in addition to a review of the relevant literature will
contribute to recognition of the disease and a decrease in
misdiagnoses.
Case presentation
A 63-year-old Chinese businessman, who had received a
kidney transplant 17 months prior because of uraemia
and who was being immunosuppressed with mycophe-
nolate mofetil (MMF), methylprednisolone (MP) and ta-
crolimus (FK506), was admitted on June 3, 2014 (day 1)
due to dyspnoea and fever lasting for two days. The pa-
tient denied having diabetes, hepatitis, or a history of
contact with people diagnosed with tuberculosis (TB).
Physical examination revealed a temperature of 38.5 °C
and decreased breath sounds at the left base with dull-
ness on percussion. A chest computed tomography (CT)
scan showed left-sided pleural effusion, along with com-
pressive atelectasis of the left lower lobe and scattered
multiple nodules on both sides, and calcification was ob-
served in the nodules in the left upper lobe (Fig. 1a–d).
The blood count showed granulopaenia and lymphopae-
nia: white blood cell (WBC) count: 2870/μl, neutrophil
(N) count: 1260/μl, lymphocyte (L) count: 540/μl, red
blood cell (RBC) count: 4,620,000/μl, haemoglobin (HB):
133 g/L, and blood platelet (PLT) count: 170,000/μl.
Left thoracentesis was performed. The fluid was a
slightly turbid yellow exudate and was negative for micro-
organisms on smear and culture (Table 1). The pleural ef-
fusion parameters were as follows: protein: 40.6 g/L, lactic
dehydrogenase (LDH): 121 IU/L, WBC count: 920/μl with
70 % lymphocytes, RBC count: 2500/μl, adenosine de-
aminase (ADA): 121 IU/L, and glucose: 7.83 mmol/L
(measured on June 4 (day 2)). All other laboratory exam-
ination results were negative: specifically, tumour markers
were normal, the PPD-S skin test result was 0 mm, the
sputum was negative for acid-fast bacilli, and sputum cul-
ture was negative.
The patient was treated with intravenous cefoperazone +
sulbactam and was kept on oral FK506, MMF and MP. His
temperature dropped to normal the day after admission
but rose three days later. Due to persistent granulopaenia
and lymphopaenia (Table 2), he was treated with re-
combinant human granulocyte colony-stimulating factor
(rhG-CSF) seven days after admission (day 8). A chest CT
was repeated 7 days later, and the left pleural effusion was
considerably decreased, but multiple nodules were still
present. The patient was then transferred to the pulmon-
ary division on June 12, 2014 (day 10).
On admission to the pulmonary division, the patient’s
body temperature was 38.1 °C, and lung examination re-
vealed decreased breath sounds at the left base, with dull-
ness on percussion. Laboratory test results included the
following: the erythrocyte sedimentation rate (ESR) was
elevated, to 60 mm/h; C-reactive protein (CRP) was ele-
vated, to 116 mg/L; the haematocrit was 37 % peripheral;
haemoglobin was 121 g/L; and the WBC count was
11,190/μl, with absolute lymphocytes at 650/μl, 86.1 %
polymorphs and 5.8 % lymphocytes. Antinuclear antigen
(ANA), extractable nuclear antigen (ENA), antineutrophil
cytoplasmic antibody (ANCA), procalcitonin (PCT), arter-
ial blood gas (ABG), blood tumour markers, and liver and
renal functions were all within the normal ranges. Add-
itionally, the sputum was negative for acid-fast bacilli and
sputum culture, and interferon gamma release assay the
(IGRA)/T-SPOT.TB were both negative.
To evaluate the pleural effusion, another thoracentesis
was performed, and the pleural fluid was still a slightly
turbid yellow exudate lacking organisms and malignant
cells (Table 1), with the following laboratory results: pro-
tein: 36.8 g/L, glucose: 4.73 IU/L, LDH: 188 IU/L, and
cell count: 470/μl (1 % N, 98 % L, 1 % Macrophage).
The cytology of the pleural fluid was nonspecific. The
lymphocyte predominance in the pleural effusion exud-
ate prompted us to test for TB AND malignancy as pos-
sible causes of the pleural effusion. The ADA level in
the fluid was 25 IU/L, and a polymerase chain reaction
(PCR) analysis of the fluid for TB was negative. More-
over, the tumour markers in the fluid were all normal,
and cultures of the pleural fluid for bacterial organisms,
mycobacteria, and fungi were all negative.
A visualized thoracoscopy was performed on June 24
(day 22). Localized pleural adhesion and diffuse thickening
were noted on the pleural surface of the thoracic cavity
(Fig. 2a–b). Disappointingly, the pleural biopsy showed
nonspecific inflammatory findings. The pathology of the
pleura was only reported as chronic, nonspecific inflamma-
tion with fibrosis. Acid-fast bacilli, granuloma and caseous
necrosis tests were all negative. Additionally, brushing of
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the intercostal pleura predominantly revealed lymphocytes,
fibrohistiocytes, and mesothelial cells without organisms or
malignant cells. There were also no notable findings in the
pleural tissues.
Although the smears and cultures for tuberculous evi-
dence were negative, given the highly endemic nature of
TB in China and the fact that the previous chest CT scan
showed fibrotic tissue and calcification, Mycobacterium
tuberculosis was considered. Therefore, the patient re-
ceived empirical anti-TB therapy with oral isoniazid, ri-
fampin, ethambutol and intravenous administration of
levofloxacin two days after the thoracoscopy (on June 26
(day 24)). On the following day, the patient occasionally
complained of headache, dizziness, vomiting and night
sweats. His temperature was even higher after taking the
anti-TB therapy, ranging from 38.2 to 39.5 °C. A lumbar
puncture was ordered, but the patient refused. A brain CT
(on June 30 (day 28)) only showed several lacunar in-
farcts in the right basal ganglia. A blood sample for
the cryptococcal antigen (CrAg) test was also ob-
tained and sent to Huashan Hospital, Fudan Univer-
sity, Shanghai, P.R. China.
On July 4 (day 32), the patient’s condition deteriorated.
His temperature was elevated to 40.2 °C, and he had a
severe headache and fainted in the ward. He was imme-
diately transferred to the respiratory intensive care unit
(RICU) immediately. His oxygen saturation had dropped
to 70 %, and ABG analysis results were pH 7.456, PaCO2
32.0 mmHg, and PaO2 56.3 mmHg. The patient ac-
cepted non-invasive ventilation and other support for
2 days. A lumbar puncture was also performed immedi-
ately, and the cerebrospinal opening pressure was
400 mm H2O (Table 3). Cryptococcus neoformans was
detected in the cerebrospinal fluid (CSF) (Fig. 2c), and
Table 1 Parameters of pleural effusion
Date: June 3 June 18
Colour: yellow, slightly turbid yellow, turbid
WBCs (/μl) 920 470
RBCs (/μl) 2500 5480
Lymphocytes (%) 70 98
Endotheliocytes (%) 30 -
Segmented cells (%) - 1
Mononuclear macrophages (%) - 1
Rivalta’s test positive positive
Total protein (g/L) 40.6 36.8
Lactate dehydrogenase (IU/L) 121 188
Glucose (mmol/L) 7.83 4.73
Adenosine deaminase (IU/L) 24 25
CEA (μg/L) 0.72 0.81
Culture:
Cryptococcus neoformans (−) (−)
M. tuberculosis (−) (−)
Smear: 920
M. tuberculosis (−) (−)
WBC white blood cell, RBC red blood cell, CEA carcinoembryonic antigen, M.
tuberculosis Mycobacterium tuberculosis
Table 2 Peripheral blood cell count
Date: June 4 June 5 June 10 June 12
WBCs (/μl) 2870 2320 1640 11190
Lymphocytes (/μl) 540 480 610 650
Neutrophils (/μl) 1730 1260 350 9630
WBC white blood cell
Fig. 1 Chest CT (2014.6.3) showed a left-sided pleural effusion with compressive atelectasis of the left lower lobe (a, b), multiple nodules scattered
in both lungs (c), and calcification in the nodules in the left upper lobe (d). Chest CT (2014.9.26) revealed that the left pleural effusion was completely
resolved (e, f), but multiple nodules and calcification were still present (g, h)
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the relevant parameters are shown in Table 3. The anti-
tuberculous agents and immunosuppressives were stopped,
and intravenous hydration and antifungal therapy were ad-
ministered. The patient was treated with amphotericin B
liposome, 5-flucytosine and voriconazole without interrup-
tion. On July 7 (day 35), the CrAg latex agglutination titres
in the serum were as high as 1:1280. Furthermore, the
serum cultures were reported twice positive for C. neofor-
mans on July 11 (day 39), one week after the lumbar
puncture. However, the pleural fluid and CSF cultures were
all negative for bacterial organisms, mycobacteria and
fungi. The serum Candida antigen test was also nega-
tive, and the β-D-glucan level was negative, at 4.5 pg/ml
(normal < 20 pg/ml).
Interestingly, follow-up of the pathological analysis of
the pleural biopsy revealed small yeast forms surrounded
by a clear halo, as determined using periodic acid-Schiff
stain (PAS) and methenamine silver stain (Fig. 2d–e).
Upon careful review of the previous pleural histological
sections (haematoxylin-eosin (HE) stained) (Fig. 2f ), a
pathologist found Cryptococcus-like organisms that had
been previously overlooked. Thus, pleural cryptococcosis
was the cause of the pleural effusion.
Disseminated cryptococcosis consisting of pleural
cryptococcosis, cryptococcal meningitis, and cryptococcal
septicaemia, was diagnosed. Considering the immunosup-
pressed state of the patient and the diagnosis of dissemi-
nated cryptococcosis with cryptococcal septicaemia, the
patient was treated with amphotericin B liposome, 5-
flucytosine and voriconazole for the first 11 days, then
amphotericin B liposome combined with 5-flucytosine
sustained to 8 weeks, which was then changed to flucona-
zole for maintenance. The left pleural effusion no longer
accumulated, and the fever, headache and dry cough
Fig. 2 Intuitive thoracoscopy revealed localized pleural adhesion and a diffuse, cellulose-like pleura (a, b). Cryptococcus neoformans was identified
by direct India ink staining of the cerebrospinal fluid (CSF) (c). Periodic acid-Schiff stain (PAS) and methenamine silver stain revealed numerous
Cryptococcus organisms in pleural sections (d, e). Re-examination of previous sections revealed Cryptococcus-like organisms that had been previously
overlooked, and the capsule was not stained (f)
Table 3 Cerebrospinal fluid parameters
Date: July 4 July 18 August 4
Colour: clear slight turbid clear
WBCs (/μl) 0 70 9
RBCs (/μl) 0 370 7
Pandy’s test slightly positive slightly positive negative
Pressure (mm H2O) ≥400 280 280
Protein (mg/L) 553 244 631
Glucose (mmol/L) <1.11 1.9 3.5
Chlorides (mmol/L) 109 111 118
Smear/Count (/μl)
Cryptococcus neoformans (+)/580 (+)/1600 (+)/410
WBC white blood cell, RBC red blood cell
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subsided. The patient improved and became asymptom-
atic three weeks after the antifungal therapy. A follow-up
chest CT (Fig. 1e–h) revealed resolution of the infiltrate.
Discussion and conclusion
C.neoformans is a nonmycelial, budding, encapsulated,
opportunistic, pathogenic, and yeast-like fungus. Inhal-
ation of either the yeast form or basidiospores from an
environmental source, such as bird droppings or soil, is
believed to cause infection with this opportunistic fun-
gus [8]. The organism may remain confined to the lungs
but also frequently disseminates to the CNS, along with
the bones, skin, and other parts of the body, depending
on the host’s immune status [9]. The most commonly
recognized form of human infection due to C. neofor-
mans is meningitis, but the fungus typically establishes
infection throughout the respiratory tract [10].
The clinical presentation of cryptococcal disease is highly
variable and occasionally consists of atypical manifesta-
tions. Cryptococcal disease can present as a cough, spu-
tum, shortness of breath, mild fever, headache, chest pain
and other symptoms, whereas nearly one-third of pulmon-
ary cryptococcosis cases were discovered by chest X-ray
due to a lack of symptoms. Disseminated disease can occur
in any organ, but the CNS is the most vulnerable. CNS dis-
ease specifically presents with headache, dizziness and
other neurological symptoms.
Reeves first described pleural effusion as a manifest-
ation of cryptococcosis in 1941 [11]. Newman et al. re-
ported the first case of cryptococcal pleural effusion in
association with acquired immune deficiency syndrome
(AIDS) [3]. With a declining incidence of AIDS-related
cryptococcosis in the highly active antiretroviral therapy
(HAART) era and with increasing use of immunosuppres-
sives worldwide, non-human immunodeficiency virus
(HIV)-infected individuals (with or without predisposing
factors) may become the predominant group affected by
cryptococcosis [12]. In Rozenbaum’s research, only one
patient manifested with pleural effusion among 11 pa-
tients who had cryptococcosis along with other diseases
or the use of immunosuppressive drugs [13]. According to
a review by Chao-Chuang Chou, pleural effusion pre-
sented in only one patient among 14 patients studied in
Taiwan [14]. Here, we report the first case of pleural effu-
sion as the initial clinical presentation in a renal transplant
recipient who was diagnosed with fungaemia and dissemi-
nated cryptococcosis. By reviewing and summarizing the
characteristics and oversights of the clinical course, we
hope to contribute to understanding of the disease and to
aid in reducing misdiagnoses. Early targeted treatment for
cryptococcal disease and intensive care may ultimately im-
prove poor prognoses.
Pleural effusion has rarely been reported as the initial
clinical presentation in cryptococcosis. To our knowledge,
only 4 cases have been reported in the English-language
literature to date [4–7]. Cryptococcosis is difficult to diag-
nose and may be overlooked, especially when pleural effu-
sion is the only clinical manifestation.
In the case described here, pathology consultation was
used to identify the aetiology of the pleural effusion. Add-
itional analyses via PAS and methenamine silver staining
revealed numerous Cryptococcus organisms in pleural
sections, providing reliable evidence of cryptococcal pleur-
itis. Regrettably, after reviewing previous HE staining, we
found Cryptococcus-like organisms (unstained capsules)
that had been overlooked in the initial examination. In this
case, the atypical manifestation of the pleural effusion,
along with the macroscopic observation and pathologiacl
study, caused the early-stage misdiagnosis. In reference to
cases reported in the literature, multiple plaques and nod-
ules have been found on the pleural surface in most cases,
and pathological findings of cryptococcal pleuritis have
shown multiple yeast-like fungal bodies in the inflamma-
tory granuloma [15].
Pleural effusion cultures for Cryptococcus are usually
negative, which make diagnosis even more difficult. Young
et al. [7] reviewed 26 cases of cryptococcal pleural effu-
sions based in English-language literature, and only 12 pa-
tients (42 %) had cultures positive for pleural effusion.
The negative culture results may have been due to the
small number of fungi in the pleural fluid. In Salyer’s opin-
ion, Cryptococcus can survive in the pleura in the form of
a granuloma that releases a large number of antigens into
pleural effusion, which is consistent with his research [16].
Similar results in our case support this theory, as the
pleural effusion cultures were negative, but the serum was
positive for cryptococcal antigens. It has been postulated
that the release of antigen, rather than organism growth,
is responsible for pleural manifestations. In particular,
various clinical manifestations (pleural effusions and
others) have been described in HIV-infected patients due
to acquired immune deficiency [17]. In the present case,
pleural effusion was observed as an unusual initial clinical
presentation in a transplant recipient with cryptococcosis.
This manifestation is not typical of cryptococcal infection
but probably occurred because our patient was on im-
munosuppressive therapy. His total CD4+ cell count
was about 200/ul, less than HIV-infected patients whose
CD4+ cell count were about 250/μl.
A cryptococcosis diagnosis is usually made by demon-
stration of the presence of the organism using histopath-
ology, culture or detection of cryptococcal antigens in
the blood and CSF, and by CrAg testing of the pleural
fluid. Detection of the capsular antigen is a reliable diag-
nostic method, and identifying Cryptococcus via histo-
pathological analysis is the gold standard for confirming
cryptococcosis. Organisms, and especially yeasts, which
are only weakly stained with HE stain, may be difficult
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to find in routine sections. Gomori-methenamine silver
stains is a characteristic black colour, and PAS stains the
yeast wall a red colour. According to the literature, the de-
tection rates of C. neoformans with these two stains are
100 % [18]. India ink staining is the traditional method for
identifying Cryptococcus by delineating the refractile mu-
cinous capsule surrounding the organism, giving the or-
ganism a characteristic “starry night” appearance. However,
the sensitivity and specificity of India ink staining can be
highly variable and are often operator-dependent.
Approximately 8 % of invasive fungal infections in solid-
organ transplant (SOT) recipients are due to cryptococ-
cosis [19]. The overall incidence of cryptococcosis in SOT
recipients is approximately 2.8 % and ranges from 0.3 to
5 %, with a mortality rate of 20 to 40 % [20, 21]. Once the
CNS is involved, the mortality rate is as high as 50 %.
Early diagnosis and treatment are crucial to improve the
survival of patients with cryptococcosis, and especially dis-
seminated cryptococcosis. In the case described here, the
patient received amphotericin B liposome combined with
5-flucytosine and voriconazole for the first 11 days, then
amphotericin B liposome combined with 5-flucytosine
sustained to 8 weeks, after which this regimen was chan-
ged to fluconazole for maintenance. The patient was still
on treatment and being followed up at the time that this
report was written.
The current guidelines from the Infectious Diseases Soci-
ety of America (IDSA) recommend treating SOT recipients
with disseminated, CNS, or severe pulmonary cryptococ-
cosis with at least 2 weeks of induction therapy with a
combination of amphotericin B lipid complex (ABLC)
and 5-flucytosine [22]. This regimen slightly differs from
Chinese expert consensus on the strategies for treating
cryptococcosis. The recommendation from Chinese ex-
perts for the management of CNS and pulmonary crypto-
coccosis in HIV-negative patients is induction therapy
with ABLC combined with 5-flucytosine for a minimum
of 8 weeks. This difference might be partly attributable to
disparities between gradually increasing the dose up to ef-
fective dose (which takes time) and administrating lower
maintaining doses of ABLC in Chinese [23].
Voriconazole, which is a synthetic derivative of flucon-
azole, is a relatively new broad-spectrum triazole with
excellent in vitro activity against C. neoformans (vorico-
nazole exhibits superior in vitro activity compared with
fluconazole), good penetration of the blood–brain bar-
rier, and extended activity against moulds and yeasts that
were not susceptible to earlier azole-type drugs [24–28].
In fact, several case studies have reported the successful
treatment of cryptococcal meningitis with voriconazole
[26–28]. The IDSA prefers to recommend amphotericin
B deoxycholate (AmBd) plus flucytosine for induction ther-
apy, rather than triple therapy (amphotericin B, flucytosine,
and fluconazole), based on data from a randomized trial by
Brouwer et al. [22]. Chinese experts suggest that triple
therapy (AmBd, flucytosine and voriconazole) could be
considered in cryptococcal meningitis patients with AIDS
[23]. We chose triple therapy (ABLC, flucytosine, and vori-
conazole) for the first 2 weeks in this patient. Because it
usually cost nearly 2 weeks for gradually increasing the
dose up to the effective dose of ABLC, voriconazole could
be an important complementary drug during this period.
But the patient’s liver function turned bad during triple
therapy, we have to stop the voriconazole on the 12th day
of antifungal therapy, triple therapy only sustained
11 days, then amphotericin B liposome combined with 5-
flucytosine sustained to 8 weeks. As we know, crypto-
coccal meningitis is fatal, even with specific treatment, so
helping patients to survive an acute attack and stabilizing
their condition for further consolidation therapy are vital.
In this case, we chose triple therapy (ABLC, flucytosine,
and voriconazole) for the first stage of induction therapy,
with a composite evaluation of safety and efficacy and
achievement of a good curative effect. Reassuringly, the
patient’s temperature returned to normal, his pleural effu-
sion was absorbed, and his general condition was good.
His cerebrospinal pressure decreased to normal, and
Cryptococcus were no longer found in the CSF.
C. neoformans-associated immune reconstitution in-
flammatory syndrome (c-IRIS) was initially observed in
HIV-infected patients receiving HAART along with rapid
reversal of immune deficiency (rapid lymphocyte CD4+
cell count recovery) [29]. The biologic basis of c-IRIS in
SOT recipients is believed to be reversal from a Th2
(anti-inflammatory) to a Th1 (pro-inflammatory) cyto-
kine profile [30–32]. The clinical presentation of c-IRIS
may be similar to that of C. neoformans meningitis.
However, c-IRIS has to be differentiated from progres-
sion of the cryptococcal disease, although both phenom-
ena can appear simultaneously [22].
The rhG-CSF is known primarily as a haematopoietic
growth factor that stimulates the production and release
of neutrophilic granulocytes from the bone marrow to
limit infection [33]. In our case, this immunosuppressed
patient was only treated with rhG-CSF once on day 8.
The patient’s condition deteriorated on day 32. rhG-CSF
is used to restore neutrophil counts and to prime neutro-
phil functions, but not lymphocyte counts and functions,
to protect vulnerable patients from infection in the clinic
[34]. Only one researcher “Hartung” reported continuous
rhG-CSF administration could increases monocyte and
lymphocyte production, intermittent rhG-CSF treatment
could not induce lymphocytosis in volunteers [35, 36]. In
this case, followed up of Lymphocytes(/μl) count showed
no increasing of Lymphocytes and CD4+ cell after usage
of rhG-CSF. The feature of c-IRIS in patients with crypto-
coccosis is CSF negative fungal culture [1]. In this case,
the finding of a positive fungal culture excluded c-IRIS
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and supported the diagnosis of progression of the crypto-
coccal disease. Therefore, c-IRIS should not be suspected
because of using rhG-CSF in this case. The relationships
between rhG-CSF therapy and c-IRIS will need to be fur-
ther scrutinized.
Cryptococcal infection must be considered in patients
with pleural effusion, and especially immunosuppressed
patients, even if culture of the pleural fluid is negative. De-
tection of cryptococcal capsular antigen in the serum and
the CSF will be useful in this context. Employing a
variety of reliable diagnostic tools, such as a bron-
choscopy with bronchoalveolar lavage, video-assisted
thoracoscopy, transbronchial biopsy, and exploratory
thoracotomy to acquire specimens in the early stages, are
also helpful for a definitive diagnosis. Careful review of
multiple stained biopsy sections and close communication
between the pathologist and the clinician are both import-
ant as well.
Consent
Written informed consent was obtained from the patient
for publication of this case. A copy of the written con-
sent is available for review by the Editor of this journal.
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